Success Metrics

Clinical Success Rate
100.0%

Based on 11 completed trials

Completion Rate
100%(11/11)
Active Trials
0(0%)
Results Posted
73%(8 trials)

Phase Distribution

Ph phase_1
2
17%
Ph phase_2
10
83%

Phase Distribution

2

Early Stage

10

Mid Stage

0

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
10(83.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

91.7%

11 of 12 finished

Non-Completion Rate

8.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(11)
Terminated(1)

Detailed Status

Completed11
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (16.7%)
Phase 210 (83.3%)

Trials by Status

withdrawn18%
completed1192%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_2

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

NCT05289037
completedphase_2

H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

NCT02921997
completedphase_1

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology

NCT03014310
completedphase_2

Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

NCT03312231
completedphase_2

2013/2017 H7N9 Prime-Boost Interval

NCT03589807
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT05289037Phase 2

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

Completed
NCT02921997Phase 2

H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

Completed
NCT03014310Phase 1

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology

Completed
NCT03312231Phase 2

Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

Completed
NCT03589807Phase 2

2013/2017 H7N9 Prime-Boost Interval

Completed
NCT03738241Phase 2

2017 A/H7N9 IIV Revaccination

Completed
NCT03318315Phase 2

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Completed
NCT03283319Phase 2

Panblok H7 Vaccine Adjuvanted With AS03 or MF59

Completed
NCT02624219Phase 1

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults

Completed
NCT00964951Phase 2

CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations

Withdrawn
NCT01942265Phase 2

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

Completed
NCT00963157Phase 2

Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12